Profund Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.85M | Sell |
14,647
-942
| -6% | -$321K | 0.18% | 89 |
|
|
2025
Q4 | $6.2M | Buy |
15,589
+12,053
| +341% | +$5.33M | 0.19% | 78 |
|
|
2025
Q3 | $1.61M | Sell |
3,536
-2,882
| -45% | -$1.17M | 0.05% | 234 |
|
|
2025
Q2 | $2.09M | Sell |
6,418
-2,408
| -27% | -$666K | 0.08% | 177 |
|
|
2025
Q1 | $2.38M | Sell |
8,826
-869
| -9% | -$223K | 0.1% | 153 |
|
|
2024
Q4 | $2.28M | Sell |
9,695
-2,379
| -20% | -$626K | 0.08% | 163 |
|
|
2024
Q3 | $3.32M | Sell |
12,074
-2,328
| -16% | -$606K | 0.13% | 125 |
|
|
2024
Q2 | $3.5M | Buy |
14,402
+5,132
| +55% | +$810K | 0.13% | 116 |
|
|
2024
Q1 | $1.39M | Buy |
9,270
+938
| +11% | +$156K | 0.05% | 265 |
|
|
2023
Q4 | $1.59M | Buy |
8,332
+1,075
| +15% | +$183K | 0.07% | 229 |
|
|
2023
Q3 | $1.29M | Sell |
7,257
-472
| -6% | -$90.1K | 0.07% | 230 |
|
|
2023
Q2 | $1.47M | Buy |
7,729
+959
| +14% | +$190K | 0.08% | 216 |
|
|
2023
Q1 | $1.36M | Sell |
6,770
-6,954
| -51% | -$1.46M | 0.08% | 210 |
|
|
2022
Q4 | $3.26M | Buy |
13,724
+636
| +5% | +$136K | 0.21% | 87 |
|
|
2022
Q3 | $2.62M | Sell |
13,088
-717
| -5% | -$137K | 0.19% | 103 |
|
|
2022
Q2 | $2.01M | Sell |
13,805
-1,170
| -8% | -$166K | 0.13% | 143 |
|
|
2022
Q1 | $2.44M | Sell |
14,975
-1,471
| -9% | -$224K | 0.1% | 170 |
|
|
2021
Q4 | $2.79M | Sell |
16,446
-2,826
| -15% | -$525K | 0.09% | 166 |
|
|
2021
Q3 | $3.64M | Sell |
19,272
-789
| -4% | -$148K | 0.12% | 142 |
|
|
2021
Q2 | $3.4M | Sell |
20,061
-552
| -3% | -$80.8K | 0.11% | 151 |
|
|
2021
Q1 | $2.91M | Sell |
20,613
-3,060
| -13% | -$460K | 0.11% | 154 |
|
|
2020
Q4 | $3.08M | Buy |
23,673
+2,117
| +10% | +$283K | 0.13% | 139 |
|
|
2020
Q3 | $3.14M | Sell |
21,556
-3,501
| -14% | -$498K | 0.16% | 111 |
|
|
2020
Q2 | $3.71M | Buy |
25,057
+4,111
| +20% | +$554K | 0.21% | 91 |
|
|
2020
Q1 | $2.28M | Sell |
20,946
-7,643
| -27% | -$882K | 0.17% | 107 |
|
|
2019
Q4 | $3.29M | Buy |
28,589
+2,996
| +12% | +$299K | 0.14% | 125 |
|
|
2019
Q3 | $2.06M | Buy |
25,593
+2,236
| +10% | +$177K | 0.1% | 178 |
|
|
2019
Q2 | $1.7M | Sell |
23,357
-2,992
| -11% | -$230K | 0.08% | 242 |
|
|
2019
Q1 | $2.46M | Buy |
26,349
+1,655
| +7% | +$138K | 0.12% | 156 |
|
|
2018
Q4 | $1.8M | Sell |
24,694
-5,926
| -19% | -$456K | 0.11% | 171 |
|
|
2018
Q3 | $2.68M | Buy |
30,620
+4,671
| +18% | +$470K | 0.1% | 175 |
|
|
2018
Q2 | $2.56M | Sell |
25,949
-1,152
| -4% | -$114K | 0.1% | 160 |
|
|
2018
Q1 | $3.23M | Sell |
27,101
-2,846
| -10% | -$367K | 0.13% | 129 |
|
|
2017
Q4 | $3.81M | Sell |
29,947
-1,502
| -5% | -$189K | 0.15% | 120 |
|
|
2017
Q3 | $3.69M | Buy |
31,449
+537
| +2% | +$45.8K | 0.15% | 111 |
|
|
2017
Q2 | $2.47M | Buy |
30,912
+1,774
| +6% | +$113K | 0.11% | 153 |
|
|
2017
Q1 | $1.49M | Sell |
29,138
-2,342
| -7% | -$108K | 0.07% | 278 |
|
|
2016
Q4 | $1.18M | Sell |
31,480
-4,984
| -14% | -$209K | 0.05% | 347 |
|
|
2016
Q3 | $2.47M | Sell |
36,464
-3,640
| -9% | -$257K | 0.12% | 144 |
|
|
2016
Q2 | $2.23M | Sell |
40,104
-1,708
| -4% | -$108K | 0.11% | 150 |
|
|
2016
Q1 | $2.63M | Sell |
41,812
-9,922
| -19% | -$660K | 0.14% | 112 |
|
|
2015
Q4 | $4.87M | Sell |
51,734
-105
| -0.2% | -$9.73K | 0.23% | 68 |
|
|
2015
Q3 | $4.17M | Sell |
51,839
-2,922
| -5% | -$325K | 0.24% | 57 |
|
|
2015
Q2 | $6.56M | Sell |
54,761
-102
| -0.2% | -$12.2K | 0.27% | 53 |
|
|
2015
Q1 | $5.73M | Buy |
54,863
+8,223
| +18% | +$833K | 0.22% | 64 |
|
|
2014
Q4 | $4.52M | Buy |
46,640
+5,004
| +12% | +$464K | 0.19% | 84 |
|
|
2014
Q3 | $3.25M | Buy |
41,636
+3,676
| +10% | +$237K | 0.15% | 106 |
|
|
2014
Q2 | $2.4M | Sell |
37,960
-6,650
| -15% | -$395K | 0.11% | 170 |
|
|
2014
Q1 | $3M | Buy |
44,610
+9,331
| +26% | +$722K | 0.14% | 111 |
|
|
2013
Q4 | $2.27M | Buy |
35,279
+7,727
| +28% | +$461K | 0.1% | 147 |
|
|
2013
Q3 | $1.76M | Buy |
+27,552
| New | +$1.37M | 0.09% | 180 |
|
Other funds holding ALNY
VPM
VCM
Profund Advisors's ALNY Position: Q1 2026 in Review
Profund Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 6% in Q1 2026, selling an estimated $321K and leaving 14,647 shares worth $4.85M. The position accounts for 0.18% of the portfolio, ranked #89.
Profund Advisors first reported a position in ALNY in Q3 2013 and has held it in 51 quarters since. The position peaked at $6.56M in Q2 2015. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Profund Advisors held 14,647 shares of Alnylam Pharmaceuticals worth $4.85M as of Q1 2026.
- Profund Advisors sold 942 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $321K.
- Alnylam Pharmaceuticals made up 0.18% of Profund Advisors's portfolio in Q1 2026, its #89 holding.
- Profund Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 51 quarters since.
- Profund Advisors's Alnylam Pharmaceuticals position peaked at $6.56M in Q2 2015.
- 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.